Get started
Author

A. Martinez Bueno

Observed names: A Martinez Bueno, A. Martínez-Bueno, Alejandro Martinez Bueno, Alejandro Martínez Bueno, Alejandro Martínez- Bueno, Alejandro Martínez-Bueno
ORCID: 0000-0002-5084-2746
Observed ORCID: 0000-0002-5084-2746
OpenAlex ID: A5073547992
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
2023 · Shubham Pant, Martin Schuler, et al. · The Lancet Oncology · 231
PDF
Adaptive resistance to targeted therapies in cancer.
2013 · Rafael Rosell, Niki Karachaliou, et al. · Europe PMC (PubMed Central) · 53
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial
2024 · M. Vaz Batista, J.M. Pérez-García, et al. · ESMO Open · 45
PDF
Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme
2022 · Juan F. Cueva, Isabel Palacio, et al. · European Journal of Cancer · 13
PDF
Efficacy and Genomic Analysis of HER2 -Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
2026 · Komal Jhaveri, Lisa D. Eli, et al. · Clinical Cancer Research · 7
PDF
Neratinib Efficacy in Patients With EGFR Exon 18-Mutant Non-Small-Cell Lung Cancer: Findings From the SUMMIT Basket Trial
2024 · Jonathan W. Goldman, Alejandro Martinez Bueno, et al. · Clinical Lung Cancer · 7
PDF
Palbociclib-induced senescence upregulates the expression of IL-8 and may enhance the response to inmunotherapy
2019 · A. Martinez Bueno, J. Bertran Aramillo, et al. · Annals of Oncology · 5
A phase Ia/IIa trial of Sym015, a MET antibody mixture, in patients with advanced solid tumours
2019 · D.R. Camidge, F. Janku, et al. · Annals of Oncology · 4
PDF
Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer
2017 · A. Martinez Bueno, M.A. Molina, et al. · Annals of Oncology · 3
29P: Evaluation of tusamitamab ravtansine, a CEACAM5-targeting antibody drug conjugate, in non-squamous NSCLC participants with negative or moderate CEACAM5 expression and high circulating CEA: Results from phase II CARMEN-LC06 trial
2025 · H. Lena, L. Paz-Ares, et al. · Journal of Thoracic Oncology · 2
PDF
6067 First line treatment with FOLFIRI-Bevacizumab for advanced colorectal cancer (ACRC): a single institution experience with 127 consecutive unselected patients
2009 · A. Ruiz de Lobera Martinez, I. Marrodan Ciordia, et al. · European Journal of Cancer Supplements · 2
258TiP A phase II trial of loperamide (L) and granulocyte colony-stimulating factors (G-CSF) to improve sacituzumab govitecan (SG) tolerance in patients (pts) with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): PRIMED
2023 · J.M. Pérez-García, M. Gion Cortes, et al. · ESMO Open · 1
PDF
271P Eribulin (E) plus endocrine therapy (ET) in patients (pts) with HR[+]/HER2[-] metastatic breast cancer (mBC) after progression on previous ET: The REVERT study
2022 · A. Lopez Gonzalez, S. Del Barco Berron, et al. · Annals of Oncology · 1
PDF
Data from Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
2026 · Komal Jhaveri, Lisa D. Eli, et al.
Figure 3 from Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
2026 · Komal Jhaveri, Lisa D. Eli, et al.
Figure 1 from Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
2026 · Komal Jhaveri, Lisa D. Eli, et al.
Table 3 from Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
2026 · Komal Jhaveri, Lisa D. Eli, et al.
Table 1 from Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
2026 · Komal Jhaveri, Lisa D. Eli, et al.
Table 2 from Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
2026 · Komal Jhaveri, Lisa D. Eli, et al.
Supplementary Data1 from Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
2026 · Komal Jhaveri, Lisa D. Eli, et al.
Figure 2 from Efficacy and Genomic Analysis of HER2-Mutant Metastatic Triple-Negative Breast Cancer Treated with Neratinib Alone or with Trastuzumab in the SUMMIT Basket Trial
2026 · Komal Jhaveri, Lisa D. Eli, et al.
Abstract 1132: Malignant effusions for cfDNA/RNA genotyping and drug testing: Turning malignant fluids into personalized cancer models
2026 · Elba Marin, Silvia Garcia-Roman, et al. · Cancer Research
460eTiP TELESCOPE: Neoadjuvant phase II study of pembrolizumab, carboplatin, and paclitaxel for stage I triple-negative breast cancer
2025 · M. Gion, A. Llombart Cussac, et al. · Annals of Oncology
55P Long-term responders (LTR) with niraparib maintenance in platinum-sensitive recurrent high-grade serous ovarian cancer (PSROC) focusing on subsequent therapies and post-progression outcomes (GEICO-88R study)
2024 · J.F. Cueva Banuelos, Y. Garcia Garcia, et al. · ESMO Open
#869 Niraparib maintenance therapy in patients aged 75 years and older with platinum-sensitive recurrent ovarian cancer: a subgroup assessment of the GEICO-88R study
2023 · Juan Cueva, Yolanda García, et al. · International Journal of Gynecological Cancer
PDF
Works count: 34
Citation count: 374
H-index: 6
I10-index: 4
Year
Topic
Type